Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets

Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.